Mulay James 4

What Happened James Mulay, a director of CG Oncology, exercised stock options to acquire a total of 1,964 shares and sold those same 1,964 shares in open-market transactions on March 16, 2026. He acquired 654 shares at $3.72 (reported cost $2,433) and 1,310 shares at $12.59 (reported cost $16,493), then sold 654 shares and 1,310 shares at $63.50 each for total proceeds of $41,529 and $83,185, respectively (combined proceeds $124,714). The exercises and same-day sales appear to be a cashless conversion and sale of the option-derived shares.

Key Details

• Transaction date: 2026-03-16; Filing date: 2026-03-17 (timely).
• Option exercises: 654 shares @ $3.72 (cost $2,433) and 1,310 shares @ $12.59 (cost $16,493).
• Open-market sales: 654 shares @ $63.50 ($41,529) and 1,310 shares @ $63.50 ($83,185); combined sales $124,714.
• Derivative entries: two derivative dispositions reported at $0 — reflect conversion/cancellation of the derivative instruments on exercise.
• Net cash realized (approx.): $124,714 proceeds minus $18,926 exercise cost ≈ $105,788.
• Shares owned after the transactions: not disclosed in the provided filing.
• Footnotes: Sales were effected under a Rule 10b5-1 trading plan adopted June 6, 2025 (F1). The related options vest in 36 monthly installments beginning July 14, 2023 (F2) and January 13, 2024 (F3).

Context This was an exercise of vested options followed by immediate sales (same-day), a common pattern for insiders monetizing vested equity. The trades were executed under a pre-established 10b5-1 plan, which schedules sales regardless of subsequent company developments; that helps avoid claims of trading on material nonpublic information but does not imply company endorsement. The filing is informational — it reports transactions, not the insider’s motivations.